Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 169 Bortezomib 92 Lenalidomide 85 daratumumab 44 Thalidomide 44 pomalidomide 43 Melphalan 40 Cyclophosphamide 33 carfilzomib 29 Calcium Dobesilate 27 Prednisone 19 Doxorubicin 16 elotuzumab 14 isatuximab 12 Filgrastim 12 ixazomib 11 Vincristine 10 Peripheral Blood Stem Cell Transplantation 10 belantamab mafodotin 9 Granulocyte Colony-Stimulating Factor 9 Zoledronic Acid 8 selinexor 7 dexamethasone acetate 7 Epoetin Alfa 7 Etoposide 6 fludarabine 5 Cisplatin 5 Carmustine 5 iberdomide 4 Radiotherapy 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Multiple Myeloma × darlin protein, Dictyostelium × Clear all

NCT03180736 2025-12-19

EMN14

European Myeloma Network B.V.

Phase 3 Completed

304 enrolled 19 charts 1 FDA

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡